The content on this site is intended for healthcare professionals only
Prof Mitch Dowsett talks to ecancertv at EBCC 9 about the research he presented on long term hormonal therapy for ER positive breast cancer.
Genetic analyses of results from 1125 postmenopausal women being treated for oestrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from ten years of hormone therapy rather than five.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
The role of lymph nodes in stage 3 lung cancer
Surgical management of Axilla: Past, present and future
